Rubicon Research Q1 FY27: Profit jumps 96% YoY

Results filed with exchanges, publications cited

Rubicon Research Limited filed its unaudited standalone and consolidated financial results for the quarter ended June 30, 2026 with the BSE and NSE on August 15, 2026. The company also stated that the results were published in the Financial Express (All India Edition) and Loksatta (Mumbai Edition), in line with SEBI LODR Regulation 47 requirements. The filing note in the provided text does not include the full financial statements, and directs investors to the company website for detailed information. Separately, the quarterly performance figures for the June 2026 quarter show a strong year-on-year improvement in revenue and profitability.

Key headline numbers for the June 2026 quarter

For the quarter ended June 2026, Rubicon Research reported sales of ₹534.34 crore, compared with ₹352.49 crore in the year-ago quarter ended June 2025. Net profit for the quarter came in at ₹84.78 crore, up from ₹43.30 crore in the corresponding period. The reported year-on-year growth rates in the supplied data were 51.59% for sales and 95.80% for net profit. Operating margin (OPM) also improved, rising to 24.16% from 22.44%.

Profitability strengthened alongside revenue growth

The supplied quarterly table shows PBDT of ₹125.51 crore in June 2026 versus ₹69.13 crore in June 2025, indicating an 82% rise. Profit before tax (PBT) was ₹110.37 crore versus ₹59.56 crore, an 85% increase. Net profit (NP) at ₹84.78 crore versus ₹43.30 crore implies that bottom-line growth outpaced top-line growth in the quarter. The increase in operating margin to 24.16% supports that pattern, suggesting improved operating leverage during the period, based on the reported numbers.

EBITDA and margin: what the quarter indicates

The text also cites operating EBITDA of ₹129.1 crore (INR 1,291 million) for Q1, up from ₹79.1 crore (₹791 million) a year earlier. On margins, EBITDA margin is stated at about 24.15% to 24.2%, compared with 22.43% to 22.4% in the year-ago quarter. Put together, these figures align with the operating profit margin (OPM) improvement shown in the June 2026 versus June 2025 table (24.16% vs 22.44%).

Acquisition contribution mentioned: Arinna Lifesciences

Rubicon Research’s commentary in the supplied text attributes part of the quarter’s performance to the Arinna acquisition completed in April 2026. The acquisition is stated to have contributed about ₹12 crore (INR 128 million) to revenue, with minimal impact on EBITDA. The same source also notes that overall revenue from operations for the quarter was ₹534.3 crore (INR 5,343 million). These disclosures position the acquisition as additive to revenue without materially diluting operating profitability, based on the information provided.

Additional metrics cited in the supplied text

Alongside the core P&L metrics, the text mentions earnings per share (EPS) of INR 5.08 for the quarter. It also includes a statement that USD revenue was $15 million for Q1, up 32% year-on-year from $12 million. Since the USD figures are presented without a reconciliation to the INR revenue number in the provided text, they are best read as an additional disclosure on currency or geography mix rather than as a substitute for the INR results.

Market context and investor disclosures

The supplied text states the stock traded little changed after the call, but it does not provide a precise percentage move for the day. Another line in the text mentions a share price of ₹1,619.1. Because the date and time for that price point are not specified in the provided content, it should be treated as a referenced price level rather than a verified closing price for the results session.

Snapshot table: Q1 performance (June quarter)

All rupee figures are normalised to ₹ crore.

Why the update matters for the pharma formulations space

The numbers in the supplied data point to a quarter where revenue growth and margin expansion occurred together. In listed pharma and formulations businesses, that combination is closely watched because it can indicate better product mix, improved manufacturing efficiency, or scale benefits. In this case, the improvement is visible in both operating margin (24.16% vs 22.44%) and profit growth (net profit up 95.80% year-on-year), as stated in the quarterly data.

What to watch next

The company has already completed the regulatory step of filing unaudited results with BSE and NSE, and noted newspaper publication under SEBI LODR Regulation 47. For investors following Rubicon Research, the next practical step is to review the detailed standalone and consolidated statements on the company’s website, as indicated in the filing note. Future updates to track, based on the provided text, include any further detail on the integration and performance contribution of the Arinna acquisition and how USD revenue trends compare with INR revenue growth across quarters.